Skip to content
CheckOrphan
  • Home
  • About Us
  • Log In
  • News
    • All News
    • Finance
    • Treatment
    • People
    • Research
  • Videos
  • Treatments
  • Clinical Trials
  • Access Programs
    • About Access Programs
  • Diseases
  • Events
  • Networks
  • Research
Main Menu

Subscribe for Free Newsletter

Email *

Type *

* Required Field
Email Marketing Services by Benchmark

Generate RSS

  1. Home
  2. /
  3. Clinical Trial
  4. /
  5. Hyperapo B and Coronary...

Hyperapo B and Coronary Heart Disease

May 27, 2020checkorphan
Learn more about:
Homozygous Familial Hypercholesterolemia
Related Clinical Trial
Hyperapo B and Coronary Heart Disease Evaluating the Efficacy of Pediatric Lipid Screening Alerts Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONET vs. the Whole Blood Apheresis System DALI PET Imaging of Inflammation and Lipid Lowering Study

Recruitment Information

Administrative Informations

Related News

  • Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for
  • Health Canada Extends the Approval of Evkeeza® (evinacumab) to Childr
  • NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase
  • Ultragenyx Receives Recommendation from NICE in the U.K. for Evkeeza®
  • Ultragenyx Receives European Commission Decision for Evkeeza® (evinac
More News

Related Clinical Trial

  • Evaluating the Efficacy of Pediatric Lipid Screening Alerts
  • Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONE
  • PET Imaging of Inflammation and Lipid Lowering Study
More Clinical Trial

Related Treatment

  • Apolipoprotein E mimetic peptide (AEM-28(R)-14)
  • Alirocumab
  • Implitapide
  • Apolipoprotein E mimetic peptide
  • Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Recep
More Treatment

Related

  • Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for
  • Health Canada Extends the Approval of Evkeeza® (evinacumab) to Childr
  • NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase
  • Ultragenyx Receives Recommendation from NICE in the U.K. for Evkeeza®
  • Ultragenyx Receives European Commission Decision for Evkeeza® (evinac
  • Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza® (evina
  • FDA approves add-on therapy for patients with genetic form of severely
  • Evaluating the Efficacy of Pediatric Lipid Screening Alerts
  • Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONE
  • PET Imaging of Inflammation and Lipid Lowering Study
More
pw

About CheckOrphan

CheckOrphan is a non-profit organization located in Basel, Switzerland and Santa Cruz, California that is dedicated to rare, orphan and neglected diseases. CheckOrphan offers users an interactive and dynamic platform for all these diseases. This strategy allows visitors to be updated daily on all the latest news and interact with people internationally. This is essential, because due to the nature of these diseases, there is not a large concentration of individuals within any given proximity.
Click here to know more About Us

Your email is important to us

Each email is sent to a CheckOrphan staff member and will be answered. We only use a contact form to avoid spam.

    Copyright © 2025 CheckOrphan.
    Developed by: Gonza.io logo Developed by: WebOptimalSolutions Powered by: Cloudscale logo